Martijn Wallert

Julius Clinical Research BV is a scientifically focused CRO that provides end-to-end clinical trial services to pharmaceutical and biotechnology customers, governments, and academia. The private company is based in the Netherlands and was founded in 2008. Julius Clinical's renowned scientific leaders are at the forefront of their fields, which combine with operational excellence and a network of research sites to deliver tailor-made solutions for customers and their clinical trials. The Dutch company has approximately 200 employees and has supported over 130 clinical trials, enrolling more than 200,000 participants in around 40 countries. Julius Clinical has a focus on the therapeutic areas of neurology, renal, cardiometabolic, and infectious diseases. The company uses its unique triangle of science, networks, and operations to provide tailored CRO and SMO services. Martijn Wallert has been the CEO of the company since 2021.

Julius Clinical Research BV is a scientifically focused CRO that provides end-to-end clinical trial services to pharmaceutical and biotechnology customers, governments, and academia. The private company is based in the Netherlands and was founded in 2008. Julius Clinical's renowned scientific leaders are at the forefront of their fields, which combine with operational excellence and a network of research sites to deliver tailor-made solutions for customers and their clinical trials. The Dutch company has approximately 200 employees and has supported over 130 clinical trials, enrolling more than 200,000 participants in around 40 countries. Julius Clinical has a focus on the therapeutic areas of neurology, renal, cardiometabolic, and infectious diseases. The company uses its unique triangle of science, networks, and operations to provide tailored CRO and SMO services. Martijn Wallert has been the CEO of the company since 2021.